Your LTC Pharmacy Explores Medication Regulation Changes
A change in medication regulation is arriving quickly for long-term care communities. Between new Centers for Medicare & Medicaid Services (CMS) surveyor guidance on psychotropics, updated expectations for drug regimen reviews, evolving telemedicine rules for controlled substances, and future requirements around electronic prescribing, administrators are facing a more complex compliance landscape than ever.
The good news is that you do not have to navigate these shifts alone. A consulting long-term care pharmacy like Angus Lake Healthcare can help your team turn regulatory pressure into a structured, manageable plan for safer medication use and stronger survey performance.
Below is an overview of key medication regulation changes affecting LTC facilities between late 2025 and 2026, and how an LTC pharmacy partnership can support your response.
Why Medication Regulation Change Is Accelerating in LTC
Regulators continue to focus on three major themes in nursing homes and other long-term care settings:
- Reducing unnecessary medications, especially psychotropics.
- Strengthening clinical oversight and documentation.
- Improving transparency around prescribing and administration.
Recent CMS and DEA actions indicate that these priorities are now reflected in day-to-day survey tools, telemedicine rules, and technology expectations.
For administrators, this means medication practices can affect:
- F tag compliance, especially F605 and F757.
- Survey outcomes and potential civil money penalties.
- Risk of resident harm and rehospitalization.
- Operational strain on already stretched nursing teams.
Your LTC pharmacy partner is uniquely positioned to interpret these changes, adjust your policies, and support your clinicians with practical workflows that enhance patient care.
Psychotropic Medications and Chemical Restraints: New Expectations
In 2025, CMS released updated Appendix PP surveyor guidance that tightened expectations around the use of psychotropic medications and chemical restraints in nursing homes. Requirements previously housed under F758 for unnecessary drugs now sit under F605, which addresses misuse of psychotropics as chemical restraints or for staff convenience.
Key elements of this medication regulation change include:
- Stronger emphasis on nonpharmacologic interventions before starting a psychotropic.
- Clearer standards for gradual dose reduction (GDR), including how to document the clinical reasons for not attempting a GDR.
- More detailed expectations for monitoring target behaviors and side effects.
- Surveyors use structured questions to evaluate whether psychotropics are truly necessary and properly managed.
For facilities, this means:
- Behavior documentation must match psychotropic orders and goals.
- Nursing notes, care plans, and pharmacy recommendations all need to tell the same story.
- GDR discussions should appear in care plan meetings and interdisciplinary notes.
How a Consulting LTC Pharmacy Helps
- Performing focused psychotropic reviews during monthly medication regimen reviews.
- Flagging residents who meet criteria for GDR or alternative therapies.
- Helping nurses document target behaviors, interventions, and outcomes more clearly.
- Providing in-service education on psychotropic risk, black box warnings, and behavior monitoring.
Drug Regimen Reviews and “Unnecessary Drugs” Under the Microscope
CMS has also refined the tools surveyors use when reviewing drug regimen oversight, especially under F757 (unnecessary medications). Updated CMS-20082 guidance gives surveyors structured interview questions for residents, families, and staff. These questions examine whether medications are effective, whether side effects are adequately monitored, and whether residents are involved in decisions about their therapy.
Surveyors now look for:
- Evidence that each medication has a current, valid clinical indication.
- Documentation of benefits, side effects, and ongoing monitoring.
- Interdisciplinary follow-up when pharmacists identify concerns.
- Regular review of PRN medications, high-risk medications, and duplicated therapies.
Facilities that treat the monthly medication regimen review as a check-box task are more vulnerable. In contrast, facilities that integrate the consulting pharmacist into care planning and quality initiatives are better positioned to demonstrate thoughtful, resident-centered medication management.
How an LTC pharmacy partner supports this change
- Conducting robust medication regimen reviews with written, actionable recommendations.
- Tracking unresolved recommendations and collaborating with medical staff on follow-up.
- Supporting deprescribing initiatives that align with CMS expectations for minimizing unnecessary drugs.
- Helping build QA projects focused on antipsychotic use, falls, or rehospitalizations tied to medication issues.
Telemedicine and Controlled Substances: New DEA Pathways
Telemedicine became standard for many communities during and after the pandemic. The DEA’s 2025 telemedicine rules continue to define how controlled substances can be prescribed remotely, including a new Advanced Telemedicine Prescribing Registration pathway. Specifically, board-certified clinicians, including physicians who treat residents in long-term care facilities, can qualify to prescribe Schedule II medications via telemedicine when specific safeguards are met.
For LTC settings, this offers potential advantages:
- Faster access to behavioral health or pain specialists.
- Reduced delays in initiating or adjusting controlled medications.
- More flexible coverage when local providers are unavailable.
Those benefits come with responsibilities. Facilities must understand:
- Which prescribers have the appropriate telemedicine registration.
- How telemedicine orders are documented and communicated.
- How to maintain secure workflows for controlled substance handling and recordkeeping.
How Your LTC Pharmacy Can Support Your Compliance
- Reviewing your controlled substance policies and electronic workflows in light of new rules.
- Helping ensure orders received via telemedicine meet DEA and state requirements before dispensing.
- Educating nursing leadership on documentation and diversion prevention in a telemedicine-heavy environment.
Electronic Prescribing for Controlled Substances: Planning for 2026 and Beyond
CMS continues to nudge prescribers toward electronic prescribing for controlled substances (EPCS). Under the EPCS program, many Medicare prescribers are required to meet electronic prescribing thresholds. For now, CMS has delayed including prescriptions written for beneficiaries in long-term care facilities in its compliance calculations until January 1, 2028.
Even with that delay, EPCS sits on the horizon. The 2026 to 2027 timeframe is an ideal planning window for facilities and pharmacy partners to:
- Confirm that prescribers serving your residents have appropriate EPCS capabilities.
- Ensure that your EHR or eMAR systems can receive and reconcile electronic controlled substance orders accurately.
- Address workflow issues such as two-factor authentication, error handling, and order clarification.
Working through these details before enforcement arrives can prevent future disruption in controlled substance access for residents.
Staffing Rules, Survey Guidance, and Their Ripple Effect on Medication Management
Staffing requirements may seem separate from medication regulation changes at first glance, yet they are closely connected in practice. In 2024, CMS finalized a federal minimum staffing rule for nursing homes that included targets for nursing hours per resident day and 24/7 RN coverage. In 2025, courts and regulators revisited that rule, and by December, CMS had repealed key minimum staffing provisions.
Even with those reversals, the message from regulators is clear:
- Facility assessments must accurately describe resident needs and staffing plans.
- Payroll-Based Journal (PBJ) data and nursing service structures are under renewed scrutiny.
- Adequate licensed oversight remains central to safe medication use.
Revised CMS guidance, effective April 28, 2025, updates nursing services and PBJ sections of Appendix PP. Surveyors will use this guidance to evaluate whether staffing supports safe care delivery, including medication administration and monitoring.
Where staffing is tight, pharmacists can help reduce risk by simplifying regimens, improving medication pass efficiency, and educating nurses on prioritizing high-risk medications.
Turning Regulatory Change Into a Safer Medication Program
Regulation changes can be overwhelming for administrators and nursing leaders who already juggle staffing shortages, complex patient care, and tight budgets. Partnering with a consulting LTC pharmacy gives your facility a dedicated ally who watches the regulatory horizon and translates rules into practical steps.
With a pharmacy partner like Angus Lake Healthcare, your facility can:
- Build psychotropic stewardship programs that align with F605 and F757.
- Integrate robust medication regimen reviews into QAPI projects.
- Provide ongoing nurse education on medication safety, documentation, and survey readiness.
- Prepare for future EPCS expectations without disrupting resident care.
- Use deprescribing, compliance packaging, and delivery services to reduce errors and lighten staff workload.
Medication regulation change is not only a compliance challenge. It is also an opportunity to strengthen your entire medication management system, protect residents from harm, and support your team with expert guidance.
If you would like support in interpreting upcoming changes and building a practical plan for your community, Angus Lake Healthcare is ready to help your facility stay compliant, confident, and focused on resident well-being.
Do you need a consulting pharmacy that strengthens your care team from the start?
Angus Lake Healthcare helps facilities stay compliant in the face of shifting regulations. Contact us today to learn how we support smarter, safer care.
Recent Articles: